Compare MIND & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIND | SCNX |
|---|---|---|
| Founded | 1987 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Other Pharmaceuticals |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.1M | 24.8M |
| IPO Year | 1994 | 2020 |
| Metric | MIND | SCNX |
|---|---|---|
| Price | $8.51 | $0.59 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 288.6K | ★ 1.8M |
| Earning Date | 12-09-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $46,195,000.00 | $653,391.00 |
| Revenue This Year | $2.33 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.14 | ★ N/A |
| Revenue Growth | 2.21 | ★ 207.88 |
| 52 Week Low | $4.45 | $0.46 |
| 52 Week High | $14.50 | $8.19 |
| Indicator | MIND | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | 40.60 | 45.74 |
| Support Level | $7.47 | $0.60 |
| Resistance Level | $9.35 | $0.75 |
| Average True Range (ATR) | 0.65 | 0.06 |
| MACD | -0.12 | 0.01 |
| Stochastic Oscillator | 34.01 | 34.54 |
MIND Technology Inc provides technology and solutions for exploration, survey, and defense applications in oceanographic, hydrographic, defense, seismic, and security industries. The company operates in segments namely, Seamap Marine Products and Klein Marine Products helps manufacture and sell specialized, high-performance sonar and seismic equipment. The company generates more revenue from Seamap Marine Products. The company's geographical segments include the United States; China, Norway; Turkey; Singapore; and Canada & Other.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.